<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Complications of spinal cord irradiation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Complications of spinal cord irradiation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Complications of spinal cord irradiation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Matthias Guckenberger, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation therapy can cause toxicity to either the central or peripheral nervous system when these structures are exposed to radiation doses beyond their tolerance. Nervous system toxicity is usually subdivided into acute (during the course of radiation), early delayed (weeks to three months after radiation), and delayed reaction (more than three months after radiation).
        </p>
        <p>
         Several syndromes of radiation injury to the spinal cord have been described, the most prominent of which are a self-limited transient myelopathy and the more serious chronic progressive myelopathy. Other more disabling manifestations of radiation injury, including acute paralysis secondary to ischemia, hemorrhage within the spinal cord, and a lower motor neuron syndrome, are much less common, with only a few case reports in the literature [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         The complications that can occur following irradiation of the spinal cord will be reviewed here. Other relevant topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complications of cranial irradiation (see
         <a class="medical medical_review" href="/z/d/html/7053.html" rel="external">
          "Acute complications of cranial irradiation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complications of irradiation of peripheral nerves (see
         <a class="medical medical_review" href="/z/d/html/5266.html" rel="external">
          "Brachial plexus syndromes", section on 'Neoplastic and radiation-induced brachial plexopathy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5267.html" rel="external">
          "Lumbosacral plexus syndromes", section on 'Radiation plexopathy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EARLY RADIATION-INDUCED MYELOPATHY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although acute central nervous system damage has been reported following brain irradiation, there is no clinical or experimental evidence that radiation induces acute spinal cord toxicity. In historical studies, single doses of up to 100 Gy did not result in immediate acute toxic effects [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         A transient radiation-induced myelopathy may develop two to six months following spinal cord irradiation. This condition is believed to represent reversible demyelination of ascending sensory neurons due to inhibition of oligodendrocyte proliferation, which makes the axons more sensitive to irritation from neck flexion. The typical duration of this acute myelopathy is approximately six months, and it is not generally a precursor of chronic progressive myelitis.
        </p>
        <p>
         The characteristic manifestation of transient radiation myelopathy is the development of Lhermitte sign, a nonpainful but unpleasant electric shock-like sensation that shoots down the spine during neck flexion. Increased spinal cord metabolic activity and positive positron emission tomography (PET) imaging have been described in association with Lhermitte sign [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The incidence of Lhermitte sign is difficult to estimate [
         <a href="#rid5">
          5-7
         </a>
         ]. In two large observational series in patients with Hodgkin lymphoma and nasopharyngeal cancer, Lhermitte sign developed in 4 and 10 percent, respectively, at a mean of three months after radiation [
         <a href="#rid5">
          5,7
         </a>
         ]. Some dose dependence of radiation to the cervical spinal cord was noted: a mean spinal cord dose of 30 Gy and spinal cord volumes exposed to doses higher than 40 Gy were described as risk factors for development of Lhermitte sign [
         <a href="#rid5">
          5,8
         </a>
         ].
        </p>
        <p>
         The differential diagnosis of Lhermitte sign in cancer patients includes tumor progression causing spinal cord compression, as well as other treatment complications, such as
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         or
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         neurotoxicity. Other causes of spinal cord disease that can result in Lhermitte sign include demyelinating diseases (eg, multiple sclerosis), vitamin B12 deficiency, and structural abnormalities of the spinal canal (eg, cervical spondylosis). (See
         <a class="medical medical_review" href="/z/d/html/2819.html" rel="external">
          "Clinical features and diagnosis of neoplastic epidural spinal cord compression"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">
          "Overview of neurologic complications of conventional non-platinum cancer chemotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">
          "Overview of neurologic complications of platinum-based chemotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1689.html" rel="external">
          "Manifestations of multiple sclerosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">
          "Treatment of vitamin B12 and folate deficiencies"
         </a>
         .)
        </p>
        <p>
         No active intervention is required other than explanation and reassurance; the syndrome usually resolves spontaneously over a period of months to a year. If the discomfort is severe,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         or
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         may be beneficial. (See
         <a class="medical medical_review" href="/z/d/html/2815.html" rel="external">
          "Cancer pain management: Role of adjuvant analgesics (coanalgesics)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          LATE RADIATION-INDUCED MYELOPATHY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Delayed injury to the spinal cord typically presents as a chronic, progressive myelopathy. Although rare, chronic progressive myelopathy is an ominous late complication of radiation. Unlike transient myelopathy, it is usually irreversible, and there is no treatment with established benefit [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Pathology and pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two types of pathologic change can occur in patients with radiation myelopathy [
         <a href="#rid10">
          10,11
         </a>
         ]. The first is damage to white matter that ranges from demyelination, through Wallerian degeneration of axons, to frank necrosis. The second change is in blood vessels that can extend from morphologically intact vessels to fibrinoid necrosis and hemorrhage [
         <a href="#rid11">
          11,12
         </a>
         ]. The degree of morphologic derangement does not always correlate with clinical severity of the myelopathy. Symptoms usually reflect the size and location of the lesions [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The pathogenesis of radiation myelopathy is incompletely understood [
         <a href="#rid13">
          13
         </a>
         ]. The adult spinal cord contains multipotential stem cells that can differentiate into oligodendroglial cells as well as astrocytes. Both oligodendroglial cells and their precursor cells can be damaged by radiation, leading to loss of myelin function. Radiation also stimulates astrocytes and microglial cells to produce cytokines. One of these cytokines, vascular endothelial growth factor (VEGF), increases the permeability of spinal cord blood vessels leading to edema [
         <a href="#rid14">
          14
         </a>
         ]. The role that this and other cytokines play in the damage to blood vessels and cellular structures of the spinal cord is unknown.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Radiation dose-volume effects and risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         The influence of dose and fractionation on the risk of chronic radiation myelopathy can be understood in three contexts: fractionated radiation, hypofractionated radiation, and reirradiation. Whereas conventional or three-dimensional (3D) conformal radiation techniques resulted in rather homogeneous dose exposure of the spinal cord, modern intensity-modulated radiotherapy techniques are frequently characterized by inhomogeneous doses within the spinal cord, both on an axial as well as on a craniocaudal level. In this context, maximum doses are considered to be most closely correlated with the risk of myelopathy. However, exposure of a large low-dose bath around a high-dose peak (shower) has been proposed to increase the risk of myelopathy [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Historically, analyses of the impact of dose and fractionation on radiation myelopathy have been inconsistently reported, in part because older treatment planning systems are less reliable in reporting maximum point dose and other parameters along the dose-volume histogram of the spinal cord. Additionally, survival has improved in many cancer types, especially in the palliative setting, which needs to be considered when interpreting historical data with only short follow-up.
        </p>
        <p class="headingAnchor" id="H376535480">
         <span class="h3">
          Fractionated radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) study, sponsored by the American Society for Radiation Oncology (ASTRO) and the American Association of Physicists in Medicine (AAPM), analyzed the literature on the risk of chronic radiation myelopathy as a function of the total dose of radiation, the extent of the spinal cord included in the treatment field, and the size of individual treatment fractions [
         <a href="#rid16">
          16
         </a>
         ]. In this review, using a conventional fractionation schedule (2 Gy per day) and including the entire cross-section of the spinal cord, total doses of 50, 60, and 69 Gy were associated with risks of chronic myelopathy of 0.2, 6, and 50 percent, respectively.
        </p>
        <p class="headingAnchor" id="H376535486">
         <span class="h3">
          Hypofractionated radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypofractionated radiation employs dose and fractionation schedules with a daily dose of ≥4 Gy per day. It is typically used in either low-dose palliative radiotherapy or in high-dose stereotactic body radiation therapy (SBRT).
        </p>
        <p>
         The QUANTEC study determined that with SBRT to a partial section of the spinal cord, the risk of radiation myelopathy with a single fraction of 13 or 20 Gy divided into three fractions was less than 1 percent [
         <a href="#rid16">
          16,17
         </a>
         ]. Subsequent data reported that for de novo SBRT delivered in one to five fractions, the following spinal cord point maximum doses (Dmax) are estimated to be associated with a 1 to 5 percent risk of radiation myelopathy: 12.4 to 14 Gy in one fraction, 17 Gy in two fractions, 20.3 Gy in three fractions, 23 Gy in four fractions, and 25.3 Gy in five fractions [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         Practice patterns from an international research consortium reported spinal cord limits that varied from 10 to 11 Gy in one fraction, 15 to 18 Gy in three fractions, and 20 to 23.75 Gy in five fractions [
         <a href="#rid20">
          20
         </a>
         ]. In most centers, these doses were applied to a 1 to 1.5 mm expansion around the spinal cord.
        </p>
        <p class="headingAnchor" id="H376535492">
         <span class="h3">
          Reirradiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of spinal reirradiation is growing as patients with spinal metastases are living longer and experiencing failures after conventional radiation therapy. In all cases of reirradiation, caution and conservatism must be used in patient selection, target delineation, and choice of cord tolerance. Preclinical data suggest that there is substantial recovery in primate spinal cord tolerance over time, to 76, 85, and 101 percent of the initial dose at one, two, and three years, respectively [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
         A retrospective study analyzed predictive factors for development of myelopathy in 40 patients treated with spine reirradiation, 11 of whom developed myelopathy after a median of 11 months [
         <a href="#rid23">
          23
         </a>
         ]. A risk score was proposed with three key parameters resulting in low risk of myelopathy: cumulative radiotherapy doses of ≤135.5 Gy (biologically effective dose [BED] with alpha/beta = 2 Gy [cervical and thoracic spine] and alpha/beta = 4 Gy [lumbar spine]), ≥6 month interval between the two radiotherapy courses, and dose of each course ≤98 Gy.
        </p>
        <p>
         The QUANTEC study reviewed 13 single-center series, all of which reported a median interval of ≥6 months between radiation courses [
         <a href="#rid16">
          16
         </a>
         ]. No cases of myelopathy were observed for cumulative doses of ≤60 Gy in 2 Gy equivalent doses.
        </p>
        <p>
         In the context of spine SBRT for reirradiation, a systematic review of the literature reported a low risk of radiation-induced myelopathy of 1.2 percent [
         <a href="#rid24">
          24
         </a>
         ]. A multicenter study concluded that reirradiation appeared to be safe when five or more months elapsed after conventional radiation and specific dosing parameters were met [
         <a href="#rid25">
          25
         </a>
         ], which was confirmed by another large multicenter analysis reporting no cases of myelopathy after SBRT reirradiation in 215 patients [
         <a href="#rid26">
          26
         </a>
         ]. A Canadian series reviewed outcomes of reirradiation after prior spine SBRT [
         <a href="#rid27">
          27
         </a>
         ]. Fifty-six spinal segments in 40 patients were previously treated with a first course of a median of 24 Gy in two fractions. At the time of progression, a salvage course of SBRT was provided with a median dose of 30 Gy in four fractions. The one-year local control was 81 percent, and no cases of myelopathy were reported.
        </p>
        <p class="headingAnchor" id="H376535797">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of radiation myelopathy range from minor sensory or motor deficits to complete paraplegia. Symptom onset is most often insidious. The latency period prior to onset of symptoms is often greater than six months. In one series, the mean latency period was 18.5 months after a first course of radiation and 11.4 months in previously irradiated patients [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         The initial signs can be subtle, such as decreased temperature sensation or decreased proprioception. These signs may stabilize or slowly but inexorably progress to lower extremity weakness, foot drop, the Brown-Sequard syndrome, incontinence, hyperreflexia, loss of bowel and bladder function, or complete paresis below the irradiated section of the spinal cord. Rarely, neurologic symptoms remit [
         <a href="#rid29">
          29,30
         </a>
         ]. Unlike with spinal metastases, back pain is absent.
        </p>
        <p class="headingAnchor" id="H2738804882">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to dose and field of radiation, there is evidence that radiosensitizing systemic agents may increase the risk of late radiation myelopathy. Case reports describe late myelopathy after radiation in combination with
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         /
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         , and high-dose
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         /
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         [
         <a href="#rid31">
          31-33
         </a>
         ].
        </p>
        <p>
         In preclinical studies, agents such as intrathecal
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         and intraperitoneal
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         enhance radiation injury to the spinal cord [
         <a href="#rid34">
          34,35
         </a>
         ]. Preclinical data also suggest that an immature spinal cord may be at higher risk for radiation myelopathy, and therefore additional caution should be used in very young patients [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H376535843">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other etiologies should be excluded prior to diagnosing chronic radiation myelopathy. The most common cause of myelopathy in cancer patients is disease progression or development of new metastases [
         <a href="#rid10">
          10
         </a>
         ]. The differential diagnosis also includes neurotoxicity caused by chemotherapy, trauma, B12 deficiency, paraneoplastic syndromes, and demyelinating diseases such as multiple sclerosis [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">
          "Disorders affecting the spinal cord"
         </a>
         .)
        </p>
        <p>
         The diagnosis of radiation myelopathy is usually made clinically and supported by spinal magnetic resonance imaging (MRI). Factors that can help clarify the role of radiation-induced damage include the dose of radiation to the spinal cord and the latency period between radiation and the onset of symptoms [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         On MRI, radiation-induced myelopathy is typically characterized by intramedullary T2 hyperintensity and T1 hypointensity spanning the affected segments. Focal contrast enhancement after gadolinium may be present. Limited data suggest that apparent diffusion coefficients (ADCs) may add additional sensitivity [
         <a href="#rid38">
          38
         </a>
         ]. Much later there may be only atrophy without evident signal abnormality [
         <a href="#rid39">
          39
         </a>
         ]. When radiotherapy records are unavailable, the radiation port can often be discerned by the hyperintense appearance of the irradiated vertebral bodies on T1-weighted images.
        </p>
        <p>
         Spinal fluid examination is usually not helpful with only an increase in the protein concentration. Evoked potentials may show a spinal conduction velocity block.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the severity of chronic progressive radiation myelopathy, a variety of treatment approaches have been suggested. However, none are supported by robust clinical data [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Glucocorticoids are the most common first treatment for radiation myelopathy. Symptomatically, some patients will respond at least partially to a trial of glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         4 to 8 mg per day). Care should be taken to use the lowest effective dose and to taper steroids in patients who do not respond clinically. Steroid myopathy related to chronic steroid use is of particular concern, as it may worsen preexisting deficits related to the myelopathy itself.
        </p>
        <p>
         Other strategies have been extensively studied in preclinical settings but have few clinical data to support their use [
         <a href="#rid41">
          41
         </a>
         ]. The strongest supporting evidence is for antiangiogenic agents such as
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , a monoclonal antibody against VEGF-A. In a small placebo-controlled randomized trial for central nervous system radiation necrosis (not specifically limited to spinal cord), bevacizumab led to both radiographic and neurologic improvements in the majority of patients [
         <a href="#rid42">
          42
         </a>
         ]. Case reports describe successful use in several patients with late radiation-induced myelopathy; however, despite improvements in imaging follow-up, only limited clinical benefit was observed [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         Some anecdotal evidence suggests that therapy with hyperbaric oxygen might be useful [
         <a href="#rid44">
          44,45
         </a>
         ], but in animal models prophylactic hyperbaric oxygen did not prevent radiation myelopathy [
         <a href="#rid46">
          46
         </a>
         ]. A study of 11 patients suggested that anticoagulation with heparin and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         could play a role in recovery of function [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         There is no clinically proven strategy to prevent the onset of radiation myelopathy. Growth factors (eg, platelet-derived growth factor, insulin-like growth factor 1, VEGF, and basic fibroblast growth factor) appear to prevent or delay radiation myelopathy in preclinical studies [
         <a href="#rid48">
          48
         </a>
         ]. In animal models, both magnesium and vitamin E ameliorate lipid peroxidation [
         <a href="#rid49">
          49
         </a>
         ], a biochemical abnormality believed to be related to radiation damage.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          OTHER LATE COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Delayed injury to the spinal cord typically is manifested by a chronic, progressive myelopathy. Less commonly, such injury can be manifested as a lower motor neuron syndrome or as a hemorrhagic injury from a radiation-induced telangiectasia or cavernous angioma.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Lower motor neuron syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The lower motor neuron syndrome was originally described after radiation therapy for testicular cancer, but this syndrome can follow any radiation therapy involving the lower spinal cord and cauda equina [
         <a href="#rid50">
          50-52
         </a>
         ]. Although this was originally thought to reflect damage to anterior horn cells, it is in fact a radiculopathy rather than a neuronopathy [
         <a href="#rid53">
          53
         </a>
         ]. The disorder follows radiation therapy by 3 to 25 years, after which patients develop slowly progressive weakness of lower extremities with little or no sensory loss and normal, or almost normal, bladder and bowel function. The magnetic resonance imaging (MRI) shows gadolinium enhancement of the roots of the cauda equina. Pathologic changes suggest a vasculopathy of proximal spinal roots with preservation of lower motor neurons within the spinal cord. Many patients remain ambulatory for many years, although weakness continues to progress.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Spinal cord hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Damage to spinal cord blood vessels can, in rare instances, lead to telangiectasia and even cavernous malformations [
         <a href="#rid6">
          6
         </a>
         ]. As many as 30 years after radiation therapy to the spinal cord, patients can develop acute hemorrhage [
         <a href="#rid2">
          2,54
         </a>
         ]. There is usually sudden onset of weakness and sensory change, sometimes associated with pain. The MRI shows evidence of acute hemorrhage. Patients usually recover.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early myelopathy
         </strong>
         – A transient radiation-induced myelopathy may develop in up to 10 percent of patients two to six months following spinal irradiation. This condition, which is manifested by Lhermitte symptom, is self-limited and does not predict for the subsequent development of chronic progressive myelopathy. (See
         <a class="local">
          'Early radiation-induced myelopathy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Late myelopathy
         </strong>
         – Chronic progressive myelopathy is an ominous late complication of radiation. Unlike transient myelopathy, it is usually irreversible. (See
         <a class="local">
          'Pathology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Radiation myelopathy is typically manifested by paresis, numbness, and sphincter dysfunction developing 6 to 12 months after irradiation. Symptoms are progressive and there is no established treatment. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above and
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The risk of chronic myelopathy after radiation is proportional to the total radiation dose, anatomic extent of spinal cord irradiation, and radiation fraction size. These risks must be understood in the contexts of fractionated radiation, hypofractionated radiation, and reirradiation. (See
         <a class="local">
          'Radiation dose-volume effects and risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lower motor neuron syndrome
         </strong>
         – The lower motor neuron syndrome is a disorder that follows radiation therapy by 3 to 25 years. Patients slowly develop progressive weakness of lower extremities with little or no sensory loss and normal, or almost normal, bladder and bowel function. (See
         <a class="local">
          'Lower motor neuron syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Spinal cord hemorrhage
         </strong>
         – Damage to spinal cord blood vessels can lead to telangiectasia and even cavernous malformations, which can result in an acute hemorrhage. (See
         <a class="local">
          'Spinal cord hemorrhage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1236058047">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Brian Kavanagh, MD, MPH, and Kevin Oh, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rock JP, Ryu S, Yin FF, et al. The evolving role of stereotactic radiosurgery and stereotactic radiation therapy for patients with spine tumors. J Neurooncol 2004; 69:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen JC, Miller DC, Budzilovich GN, Epstein FJ. Brain and spinal cord hemorrhage in long-term survivors of malignant pediatric brain tumors: A possible late effect of therapy. Neurology 1991; 41:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tefft M, Mitus A, Schulz MD. Initial high dose irradiation for metastases causing spinal cord compression in children. Am J Roentgenol Radium Ther Nucl Med 1969; 106:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esik O, Csere T, Stefanits K, et al. Increased metabolic activity in the spinal cord of patients with long-standing Lhermitte's sign. Strahlenther Onkol 2003; 179:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fein DA, Marcus RB Jr, Parsons JT, et al. Lhermitte's sign: Incidence and treatment variables influencing risk after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys 1993; 27:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Word JA, Kalokhe UP, Aron BS, Elson HR. Transient radiation myelopathy (Lhermitte's sign) in patients with Hodgkin's disease treated by mantle irradiation. Int J Radiat Oncol Biol Phys 1980; 6:1731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung WM, Tsang NM, Chang FT, Lo CJ. Lhermitte's sign among nasopharyngeal cancer patients after radiotherapy. Head Neck 2005; 27:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pak D, Vineberg K, Feng F, et al. Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms. Int J Radiat Oncol Biol Phys 2012; 83:1528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong CS, Fehlings MG, Sahgal A. Pathobiology of radiation myelopathy and strategies to mitigate injury. Spinal Cord 2015; 53:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schultheiss TE, Kun LE, Ang KK, Stephens LC. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 1995; 31:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okada S, Okeda R. Pathology of radiation myelopathy. Neuropathology 2001; 21:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schultheiss TE, Stephens LC, Maor MH. Analysis of the histopathology of radiation myelopathy. Int J Radiat Oncol Biol Phys 1988; 14:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieder C, Ataman F, Price RE, Ang KK. Radiation myelopathy: New perspective on an old problem. Radiat Oncol Investig 1999; 7:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordal RA, Nagy A, Pintilie M, Wong CS. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: A role for vascular endothelial growth factor. Clin Cancer Res 2004; 10:3342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philippens ME, Pop LA, Visser AG, et al. Bath and shower effect in spinal cord: the effect of time interval. Int J Radiat Oncol Biol Phys 2009; 73:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010; 76:S42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimm J, Sahgal A, Soltys SG, et al. Estimated Risk Level of Unified Stereotactic Body Radiation Therapy Dose Tolerance Limits for Spinal Cord. Semin Radiat Oncol 2016; 26:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahgal A, Chang JH, Ma L, et al. Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2021; 110:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ong WL, Wong S, Soliman H, et al. Radiation myelopathy following stereotactic body radiation therapy for spine metastases. J Neurooncol 2022; 159:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guckenberger M, Sweeney RA, Flickinger JC, et al. Clinical practice of image-guided spine radiosurgery--Results from an international research consortium. Radiat Oncol 2011; 6:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ang KK, Jiang GL, Feng Y, et al. Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys 2001; 50:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ang KK, Price RE, Stephens LC, et al. The tolerance of primate spinal cord to re-irradiation. Int J Radiat Oncol Biol Phys 1993; 25:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieder C, Grosu AL, Andratschke NH, Molls M. Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. Int J Radiat Oncol Biol Phys 2005; 61:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myrehaug S, Sahgal A, Hayashi M, et al. Reirradiation spine stereotactic body radiation therapy for spinal metastases: systematic review. J Neurosurg Spine 2017; 27:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahgal A, Ma L, Weinberg V, et al. Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2012; 82:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hashmi A, Guckenberger M, Kersh R, et al. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis. J Neurosurg Spine 2016; 25:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thibault I, Campbell M, Tseng CL, et al. Salvage stereotactic body radiotherapy (SBRT) following in-field failure of initial SBRT for spinal metastases. Int J Radiat Oncol Biol Phys 2015; 93:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong CS, Van Dyk J, Milosevic M, Laperriere NJ. Radiation myelopathy following single courses of radiotherapy and retreatment. Int J Radiat Oncol Biol Phys 1994; 30:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esik O, Emri M, Csornai M, et al. Radiation myelopathy with partial functional recovery: PET evidence of long-term increased metabolic activity of the spinal cord. J Neurol Sci 1999; 163:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lengyel Z, Rékó G, Majtényi K, et al. Autopsy verifies demyelination and lack of vascular damage in partially reversible radiation myelopathy. Spinal Cord 2003; 41:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruckdeschel JC, Baxter DH, McKneally MF, et al. Sequential radiotherapy and adriamycin in the management of bronchogenic carcinoma: The question of additive toxicity. Int J Radiat Oncol Biol Phys 1979; 5:1323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloss JD, DiSaia PJ, Mannel RS, et al. Radiation myelitis: A complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix. Gynecol Oncol 1991; 43:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seddon BM, Cassoni AM, Galloway MJ, et al. Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: A review of the literature and implications for practice. Clin Oncol (R Coll Radiol) 2005; 17:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruifrok AC, van der Kogel AJ. The effect of intraspinal cytosine arabinoside on the re-irradiation tolerance of the cervical spinal cord of young and adult rats. Eur J Cancer 1993; 29A:1766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grégoire V, Ruifrok AC, Price RE, et al. Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation. Radiother Oncol 1995; 36:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruifrok AC, Stephens LC, van der Kogel AJ. Radiation response of the rat cervical spinal cord after irradiation at different ages: Tolerance, latency and pathology. Int J Radiat Oncol Biol Phys 1994; 29:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werner-Wasik M, Yu X, Marks LB, Schultheiss TE. Normal-tissue toxicities of thoracic radiation therapy: Esophagus, lung, and spinal cord as organs at risk. Hematol Oncol Clin North Am 2004; 18:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philippens ME, Gambarota G, van der Kogel AJ, Heerschap A. Radiation effects in the rat spinal cord: Evaluation with apparent diffusion coefficient versus T2 at serial MR imaging. Radiology 2009; 250:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komachi H, Tsuchiya K, Ikeda M, et al. Radiation myelopathy: A clinicopathological study with special reference to correlation between MRI findings and neuropathology. J Neurol Sci 1995; 132:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung C, Bryant A, Brown PD. Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery. Cochrane Database Syst Rev 2018; 7:CD011492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matis GK, Birbilis TA. Erythropoietin in spinal cord injury. Eur Spine J 2009; 18:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011; 79:1487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Psimaras D, Tafani C, Ducray F, et al. Bevacizumab in late-onset radiation-induced myelopathy. Neurology 2016; 86:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrò F, Jinkins JR. MRI of radiation myelitis: A report of a case treated with hyperbaric oxygen. Eur Radiol 2000; 10:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luk KH, Baker DG, Fellows CF. Hyperbaric oxygen after radiation and its effect on the production of radiation myelitis. Int J Radiat Oncol Biol Phys 1978; 4:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sminia P, van der Kleij AJ, Carl UM, et al. Prophylactic hyperbaric oxygen treatment and rat spinal cord re-irradiation. Cancer Lett 2003; 191:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glantz MJ, Burger PC, Friedman AH, et al. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 1994; 44:2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andratschke NH, Nieder C, Price RE, et al. Potential role of growth factors in diminishing radiation therapy neural tissue injury. Semin Oncol 2005; 32:S67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peker S, Abacioglu U, Sun I, et al. Prophylactic effects of magnesium and vitamin E in rat spinal cord radiation damage: Evaluation based on lipid peroxidation levels. Life Sci 2004; 75:1523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esik O, Vönöczky K, Lengyel Z, et al. Characteristics of radiogenic lower motor neurone disease, a possible link with a preceding viral infection. Spinal Cord 2004; 42:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feistner H, Weissenborn K, Münte TF, et al. Post-irradiation lesions of the caudal roots. Acta Neurol Scand 1989; 80:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tallaksen CM, Jetne V, Fosså S. Postradiation lower motor neuron syndrome--A case report and brief literature review. Acta Oncol 1997; 36:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowen J, Gregory R, Squier M, Donaghy M. The post-irradiation lower motor neuron syndrome neuronopathy or radiculopathy? Brain 1996; 119 (Pt 5):1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabbour P, Gault J, Murk SE, Awad IA. Multiple spinal cavernous malformations with atypical phenotype after prior irradiation: Case report. Neurosurgery 2004; 55:1431.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7066 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15527098" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The evolving role of stereotactic radiosurgery and stereotactic radiation therapy for patients with spine tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1985281" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Brain and spinal cord hemorrhage in long-term survivors of malignant pediatric brain tumors: a possible late effect of therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4307628" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Initial high dose irradiation for metastases causing spinal cord compression in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14566477" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Increased metabolic activity in the spinal cord of patients with long-standing Lhermitte's sign.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8262823" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Lhermitte's sign: incidence and treatment variables influencing risk after irradiation of the cervical spinal cord.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7239993" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Transient radiation myelopathy (Lhermitte's sign) in patients with Hodgkin's disease treated by mantle irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15627248" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lhermitte's sign among nasopharyngeal cancer patients after radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22284690" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25800695" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pathobiology of radiation myelopathy and strategies to mitigate injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7677836" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Radiation response of the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11837531" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pathology of radiation myelopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3275603" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Analysis of the histopathology of radiation myelopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10492160" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Radiation myelopathy: new perspective on an old problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15161688" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19046823" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Bath and shower effect in spinal cord: the effect of time interval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20171517" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Radiation dose-volume effects in the spinal cord.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27000514" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Estimated Risk Level of Unified Stereotactic Body Radiation Therapy Dose Tolerance Limits for Spinal Cord.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31606528" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35737172" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Radiation myelopathy following stereotactic body radiation therapy for spine metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22172095" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical practice of image-guided spine radiosurgery--results from an international research consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11429229" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Extent and kinetics of recovery of occult spinal cord injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8436524" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The tolerance of primate spinal cord to re-irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15708265" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28708043" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Reirradiation spine stereotactic body radiation therapy for spinal metastases: systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20951503" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Reirradiation human spinal cord tolerance for stereotactic body radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27341054" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26383680" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7928488" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Radiation myelopathy following single courses of radiotherapy and retreatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10223408" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Radiation myelopathy with partial functional recovery: PET evidence of long-term increased metabolic activity of the spinal cord.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14504618" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Autopsy verifies demyelination and lack of vascular damage in partially reversible radiation myelopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/528285" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Sequential radiotherapy and adriamycin in the management of bronchogenic carcinoma: the question of additive toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1752503" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Radiation myelitis: a complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16097572" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8398307" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The effect of intraspinal cytosine arabinoside on the re-irradiation tolerance of the cervical spinal cord of young and adult rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8525025" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8175448" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Radiation response of the rat cervical spinal cord after irradiation at different ages: tolerance, latency and pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15005286" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Normal-tissue toxicities of thoracic radiation therapy: esophagus, lung, and spinal cord as organs at risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19037019" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Radiation effects in the rat spinal cord: evaluation with apparent diffusion coefficient versus T2 at serial MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8543953" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Radiation myelopathy: a clinicopathological study with special reference to correlation between MRI findings and neuropathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29987845" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19030901" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Erythropoietin in spinal cord injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20399573" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26740673" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Bevacizumab in late-onset radiation-induced myelopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11003402" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : MRI of radiation myelitis: a report of a case treated with hyperbaric oxygen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/689946" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Hyperbaric oxygen after radiation and its effect on the production of radiation myelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12609710" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prophylactic hyperbaric oxygen treatment and rat spinal cord re-irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7969953" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Treatment of radiation-induced nervous system injury with heparin and warfarin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16015538" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Potential role of growth factors in diminishing radiation therapy neural tissue injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15240186" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prophylactic effects of magnesium and vitamin E in rat spinal cord radiation damage: evaluation based on lipid peroxidation levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14765142" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Characteristics of radiogenic lower motor neurone disease, a possible link with a preceding viral infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2554633" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Post-irradiation lesions of the caudal roots.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9208910" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Postradiation lower motor neuron syndrome--a case report and brief literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8931568" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The post-irradiation lower motor neuron syndrome neuronopathy or radiculopathy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15574226" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Multiple spinal cavernous malformations with atypical phenotype after prior irradiation: case report.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
